NCT02992314已完成不适用
Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste
You First Services2 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2017年5月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 52
- 试验地点
- 2
- 主要终点
- Relief of medication associated metallic taste
研究概览
简要总结
Patients taking chemotherapeutic agents often do not comply well with their dosing regiment since many of these medications cause a metallic taste in the mouth. The primary intent is to determine the effectiveness of the oral rinse in reducing the metallic taste in the mouth associated with various chemotherapeutic agents. This clinical study a randomized, double-blind, single-treatment, parallel design with a placebo as the control. The duration of the trial will be 1 month.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has read, signed and received a copy of the Informed Consent and HIPAA authorization prior to study initiation.
- •Subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified study examinations.
- •Subject is between the ages of 18 and 75 years inclusive.
- •Subject will not have professional cleaning during the 3-month trial.
- •Subject has no history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test drug, as determined by the Principal Investigator.
- •Subject has a minimum of 16 natural teeth and a complaint of moderate to severe medication associated metallic taste.
- •Subject agrees to refrain from the use of any oral rinse, toothpaste or dentifrice other than the Colgate® Cavity Protection Fluoride toothpaste and study rinse provided on Visit 1 for the duration of the study.
- •Subject agrees to refrain from the use of other oral care products not supplied by the study center
- •Subject agrees to be compliant with study procedures.
- •Females of childbearing potential agree to use an adequate method of birth control and agree to pregnancy testing at the first and second visit.
排除标准
- •Subject has a condition that requires prophylactic antibiotics for dental examinations and treatments (e.g., has a history of valvular heart disease or a recently placed prosthetic joint).
- •Subject has disqualifying acute or chronic medical illness as judged by the Principal Investigator.
- •Subject is currently taking phenytoin, cyclosporin, nifedipine or any other drug that has been shown to cause gingival enlargement or affect the gingivae.
- •Subject has taken antibiotics, steroids, or non-steroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen) within one week prior to baseline examination. Subjects taking long-term aspirin (81 mg/day) may be included in the trial, but subjects taking a larger dose will be excluded. Subjects taking blood thinners such as Coumadin (warfarin), Lovenox, or Plavix will be excluded.
- •Subject is pregnant (based on pregnancy result) or lactating.
结局指标
主要结局
Relief of medication associated metallic taste
时间窗: 4 weeks
Have patient complete a VAS ( visual analogue scale) scoring of the degree of metallic taste in the mouth as well as a VAS scoring of the amount of relief of the metallic taste..
次要结局
- Safety evaluation of the test Oral Rinse(4 Weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
High-Dose Methotrexate in Treating Young Patients With Solid TumorsBrain and Central Nervous System TumorsUnspecified Childhood Solid Tumor, Protocol SpecificSarcomaNCT00513981Children's Cancer and Leukaemia Group36
暂停
不适用
Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional ChemotherapyLymphomaSarcomaNCT01921998The Christie NHS Foundation Trust50
已完成
不适用
Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin LymphomaClassical Hodgkin LymphomaNodular SclerosisMixed CellularityLymphocyte DepletionLymphocyte RichNCT00305149Rambam Health Care Campus130
已完成
1 期
L-778,123 in Treating Patients With Recurrent or Refractory Solid TumorsHead and Neck CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00003430Memorial Sloan Kettering Cancer Center40
撤回
2 期
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous LeukemiaLeukemiaNCT00003405Rush University Medical Center